Proteomics and metabolomics in inflammatory bowel disease
Yunki Yau1, Rupert W Leong, Ming Zeng
1Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, Australia.
Journal of Gastroenterology and Hepatology
|March 16, 2013
Summary
Proteomics and metabolomics offer new insights into inflammatory bowel disease (IBD) origins and pathways. Integrating complex data is key to translating these findings into improved patient prognosis and outcomes for Crohn's disease and ulcerative colitis.
Area of Science:
- * Gastroenterology and immunology
- * Genomics, proteomics, and metabolomics
Background:
- * Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is understood as a group of autoinflammatory disorders with diverse pathogenic origins.
- * Genomic studies have laid the groundwork for understanding IBD's complexity.
- * Proteomics and metabolomics have emerged as powerful tools to explore underlying pathogenic mechanisms.
Purpose of the Study:
- * To review the historical context and advancements in IBD clinical development.
- * To assess the impact of proteomics and metabolomics on IBD research.
- * To discuss challenges and future directions for integrating complex biological data with clinical applications in IBD prognosis.
Main Methods:
- * Review of existing literature on IBD, genomics, proteomics, and metabolomics.
- * Analysis of the application and findings of proteomics and metabolomics in IBD studies over the past decade and five years, respectively.
- * Discussion of data integration challenges and potential solutions.
Main Results:
- * Proteomics and metabolomics have provided novel findings regarding IBD pathogenesis.
- * Significant challenges exist in consolidating high-complexity omics data with physiological understanding.
- * Translating these research findings into tangible patient benefits remains a hurdle.
Conclusions:
- * Proteomics and metabolomics are crucial for characterizing unknown pathogenic pathways in IBD.
- * Overcoming data integration challenges is essential for clinical translation.
- * Emerging principles are needed to bridge bioanalytical laboratory findings with IBD patient prognosis.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...